OncoSec Medical Inc (ONCSQ)

[twiz0019]

As evidenced by the recent peer-reviewed PR, Dr. Pierce is still very much involved with ONCS and has not left the company. Quote..

"This paper supports the concept that the 'target cell' of anti-PD-1 monoclonal antibodies (mAb) is the partially exhausted CD8+ T-cell within the tumor, which can be readily quantified using flow cytometry," said Robert H. Pierce, MD, OncoSec Chief Scientific Strategist and co-author of the paper.